Credit score: Pixabay/CC0 Public Area
US well being regulators have permitted a brand new antibiotic to deal with urinary tract infections, an issue affecting greater than 100 million individuals around the globe, primarily girls, British pharmaceutical big GSK mentioned Tuesday.
The corporate mentioned the US Meals and Drug Administration permitted using the product—referred to as Blujepa—for therapy of so-called uncomplicated urinary tract infections in grownup girls and women 12 and older.
It’s the first in a brand new class of oral antibiotics for urinary tract infections, mentioned GSK scientific director Tony Wooden, who referred to as the FDA approval a “essential milestone.”
Whereas different antibiotics exist for treating these infections, this new drug will “deliver one other choice to sufferers given recurrent infections and rising charges of resistance to current remedies,” Wooden mentioned.
Repeated use of antibiotics has led to the emergence of micro organism which might be an increasing number of resistant, making the infections they trigger more durable to remedy.
A examine revealed in 2019 concluded that 92% of micro organism that trigger urinary tract infections are immune to at the very least one antibiotic and 80% are immune to at the very least two.
© 2025 AFP
Quotation:
US approves new antibiotic for urinary tract infections (2025, March 26)
retrieved 26 March 2025
from https://medicalxpress.com/information/2025-03-antibiotic-urinary-tract-infections.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
